The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1

Cell Calcium. 2008 Mar;43(3):270-84. doi: 10.1016/j.ceca.2007.05.017. Epub 2007 Jul 24.

Abstract

In human neutrophils, the neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) acting via the G protein-coupled receptors vasoactive intestinal peptide/PACAP receptor 1 (VPAC-1) and formyl peptide receptor-like 1 (FPRL1) modulates Ca2+ and pro-inflammatory activities. We evaluated in human monocytes the importance of the Ca2+ signal and the participation of FPRL1 in PACAP-associated signaling pathways and pro-inflammatory activities. PACAP-evoked Ca2+ transient involved both Ca2+ influx and intracytoplasmic Ca2+ mobilisation. This was pertussis toxin, protein kinase A and adenylate cyclase dependent indicating the participation of Galphai and Galphas with mobilisation of both InsP3 sensitive and insensitive stores. Intra- or extracellular Ca2+ depletion resulted in the inhibition of PACAP-induced, Akt, ERK, p38 and NF-kappaB activations as well as a decrease in PACAP-associated reactive oxygen species (ROS) production and integrin CD11b membrane upregulation. The FPRL1 antagonist, Trp-Arg-Trp-Trp-Trp (WRW4), decreased PACAP-evoked Ca2+ signal, Akt, ERK phosphorylation, ROS and CD11b upregulation without affecting p38 phosphorylation. NF-kappaB inhibitors prevented PACAP-induced Ca2+ mobilisation. Monocytes pre-treatment with fMLP but not with LPS desensitised cells to the pro-inflammatory effects of PACAP. Thus, both intra- and extracellular Ca2+ play a role in controlling pro-inflammatory functions stimulated by PACAP which acts through a VPAC-1, FPRL1/Galphai/PI3K/ERK pathway and a VPAC-1/Galphas/PKA/p38 pathway to fully activate monocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD11b Antigen / metabolism
  • Calcium / metabolism*
  • Calcium Signaling / drug effects
  • Enzyme Activation / drug effects
  • Extracellular Space / drug effects
  • Extracellular Space / metabolism
  • GTP-Binding Protein alpha Subunits, Gi-Go / metabolism
  • GTP-Binding Protein alpha Subunits, Gs / metabolism
  • Humans
  • Inflammation / metabolism*
  • Intracellular Space / drug effects
  • Intracellular Space / metabolism
  • Mitogen-Activated Protein Kinases / metabolism
  • Monocytes / drug effects*
  • Monocytes / enzymology
  • Monocytes / metabolism*
  • NF-kappa B / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation / drug effects
  • Pituitary Adenylate Cyclase-Activating Polypeptide / pharmacology*
  • Protein Binding / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Formyl Peptide / metabolism*
  • Receptors, Lipoxin / metabolism*
  • Receptors, Vasoactive Intestinal Polypeptide, Type I / metabolism*
  • Respiratory Burst / drug effects

Substances

  • CD11b Antigen
  • FPR2 protein, human
  • NF-kappa B
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Formyl Peptide
  • Receptors, Lipoxin
  • Receptors, Vasoactive Intestinal Polypeptide, Type I
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinases
  • GTP-Binding Protein alpha Subunits, Gi-Go
  • GTP-Binding Protein alpha Subunits, Gs
  • Calcium